In Brief: Novartis, Abbott Earnings; Using mL Cuts Mis-Dosing; Labels Need Proprietary Blend, Capsule Ingredients

Novartis consumer up 5%; adult products drive Abbott Nutrition growth; medication errors drop when mL is unit of measurement; ingredients of proprietary blends must be labeled; include capsule ingredients on labels; and Herbalife defends nutrition clubs.

Novartis AG’s consumer business gathers steam in advance of moving into a joint venture with GlaxoSmithKline PLC as net sales in its fiscal 2014 second quarter grow 5% to $1.1 billion, driven by “solid OTC performance across key regions.” The Swiss firm July 17 said the cessation of depreciation and amortization of non-current assets in advance of its consumer business change had a positive impact of $18 million for the April-June period, comprising $8 million for depreciation and $10 million for amortization. Novartis and GSK in April agreed to combine their consumer portfolios in a JV they estimate will have annual OTC sales of $5.72 billion ([A#05140428004]). The deal, expected to close in first half of 2015, should strengthen GSK’s consumer products business and help Novartis recover from widespread OTC business setbacks linked to quality-control problems. In its earnings release, Novartis said all of the 60 regulatory inspections of its manufacturing sites during the quarter, including four by FDA, “were deemed acceptable or good.” The firm’s total net sales grew 2% to $14.6 billion and its income increased 6% to $3.8 billion. Novartis forecasts growth in 2014 net sales in the low to mid-single digit rate and operating income in the mid to high-single digit rate.

Ensure and other adult product sales drive [Abbott Nutrition] growth as a 2013 interruption to pediatric product sales in China...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Some Laid Off Employees Called Back At US FDA

 

Some FDA employees who were recently laid off by the Trump Administration are being called back to work, multiple sources confirmed to the Pink Sheet.

US Proposal To Remove Phenylephrine From OTC Monograph Could Stress-Test Streamlined Process

 

Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.

FDA Clears Qnovia’s NRT Inhalation IND, Commits To ‘Stimulating’ Smoking Cessation Innovation

 

Qnovia notes NRT inhalation product recently received investigational new drug clearance from FDA as agency and NIH say innovation needed smoking cessation to help improve rate of success for quitting the habit that kills around 500,000 US consumers annually.

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.